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The HIV envelope glycoprotein (Env) trimer un-
dergoes receptor-induced conformational changes
that drive fusion of the viral and cellular membranes.
Env conformational changes have been observed
using low-resolution electron microscopy, but only
large-scale rearrangements have been visible. Here,
we use hydrogen-deuterium exchange and oxidative
labeling to gain a more precise understanding of the
unliganded and CD4-bound forms of soluble Env
trimers (SOSIP.664), including their glycan composi-
tion. CD4 activation induces the reorganization of
bridging sheet elements, V1/V2 and V3, much of the
gp120 inner domain, and the gp41 fusion subunit.
Two CD4 binding site-targeted inhibitors have sub-
stantially different effects: NBD-556 partially mimics
CD4-induced destabilization of the V1/V2 and V3
crown, whereas BMS-806 only affects regions
around the gp120/gp41 interface. The structural
information presented here increases our knowledge
of CD4- and small molecule-induced conformational
changes in Env and the allosteric pathways that lead
to membrane fusion.
INTRODUCTION
The trimeric envelope glycoprotein (Env) complex on the surface
of virions mediates HIV-1 entry and is the sole target for neutral-
izing antibodies (NAbs) that are induced during natural infection.
A detailed understanding of Env’s structure, its conformational
rearrangements, and how it presents NAb epitopes is critical
for guiding the design of both protein-based vaccines and
Env-targeting entry inhibitors (Jardine et al., 2013; Walker and
Burton, 2010). The 4.7 A˚ crystal and 5.8 A˚ cryo-electron micro-
scopy (cryo-EM) structures of a soluble, cleaved form of the
Env trimer (BG505 SOSIP.664) have unveiled novel aspects of
its antigenicity and architecture (Julien et al., 2013a; Lyumkis
et al., 2013). However, the complete organization of gp41 and974 Structure 22, 974–984, July 8, 2014 ª2014 Elsevier Ltd All rightsthe mechanism underlying CD4-induced structural reorganiza-
tions within the trimer remain unresolved. It also is necessary
to understand how flexible elements, including gp120 glycans
and surface loops, and the ‘‘breathing’’ of the overall Env com-
plex modulate its recognition by antibodies and host factors
(Davenport et al., 2013; Kwong et al., 2002; Myszka et al.,
2000; Scanlan et al., 2007).
Characterizing conformational changes in multisubunit glyco-
protein complexes via classical structural methods can be very
challenging. Here, we probe the structural dynamics of the Env
trimer using hydrogen-deuterium exchange (HDX) to measure
the rates of deuterium incorporation into backbone amides
under solution conditions. Unstructured or flexible regions
undergo deuterium exchange rapidly, in marked contrast to
ones involved in stable hydrogen bonding networks as part of
the protein secondary structure or those that are highly occluded
from solvent. Coupled with mass spectrometry (MS), HDX infor-
mation can be used to measure conformation dynamics with
sequence-specific detail, localize protein-protein interactions,
and detect ligand-induced conformational changes (Marcsisin
and Engen, 2010). As a complementary approach, we performed
oxidative labeling using short exposures to synchrotron radiation
to generate hydroxyl radicals that modify protein side chains.
Because solvent-occluded side chains react less readily than
exposed ones, this method allows solvent accessibility to be
estimated, in some cases with single amino acid resolution
(Tong et al., 2008; Wang and Chance, 2011).
We have used these techniques to study soluble, cleaved
SOSIP.664 trimers based on the subtype A sequences
KNH1144 and BG505. The sequence modifications used to
stabilize these trimers are described elsewhere and summarized
in Figure 1A (Binley et al., 2000, 2002; Sanders et al., 2002b,
2013). The resulting homogeneous trimers closely resemble
native Env on virions, both antigenically and structurally (Harris
et al., 2011; Khayat et al., 2013; Sanders et al., 2013). Here we
report a structural analysis of the BG505 SOSIP.664 trimer in
its unliganded prefusion and CD4-bound states. The HDX results
reveal the nature of rearrangements in the gp120 receptor bind-
ing subunit and the allosteric changes in the gp41 fusion subunit.
The sequence-specific details complement electron microscopy
structures of prefusion and CD4-bound trimers (Harris et al.,
2011; Liu et al., 2008; Tran et al., 2012).reserved
Figure 1. HDX Profile of SOSIP.664 Trimers
(A) The sequence of mature, full-length Env is
shown with the SOSIP modifications indicated. To
the right, structural elements including variable
loops 1 to 5, N/C termini, and heptad repeats of
gp41 (HR1 and HR2) are mapped onto the ribbon
diagram for one protomer from the BG505
SOSIP.664 trimer crystal structure (Protein Data
Bank [PDB] accession number 4NCO) (Julien
et al., 2013a).
(B and C) The HDX profiles are shown for
unliganded BG505 and KNH1144 SOSIP.664
trimers. Percentage exchange is shown after 3 s,
1 min, 30 min, and 20 hr for all observable peptic
fragments at the midpoint of their primary
sequence. For example, the exchange profile of
the peptide from residue 105 to 111 is plotted at
position 108. Individual exchange plots with errors
are shown in Figures S2 and S3.
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that target the CD4 binding site: BMS-806 and NBD-556. The
binding of NBD-556 to a monomeric gp120 core fragment has
been studied via thermodynamic measurements and X-ray
crystallography (Kwon et al., 2012; Scho¨n et al., 2006; Zhao
et al., 2005). NBD-556 binding has a major effect at the apex of
the SOSIP.664 trimer, which is substantially different than what
was seen using monomeric gp120. In contrast, BMS-806 does
not affect the apex of the trimer, consistent with its inhibition of
CD4-induced conformational changes (Guo et al., 2003; Lin
et al., 2003; Madani et al., 2004). Overall, our studies of how the
HIV-1 Env trimer interacts with CD4, NBD-556, and BMS-806
provide insights into the allosteric networks that are involved in
the receptor-mediated activation of this type 1 fusion protein.
RESULTS
HDX-MS Profile of SOSIP.664 Trimers
The KNH1144 and BG505 SOSIP.664 trimers were analyzed by
HDX-MS. After optimizing pepsin digestion conditions,
sequence coverage of 92% (89% of gp120 and 100% of gp41)
from 103 unique KNH1144 peptides and 82% (76% of gp120
and 100% of gp41) from 120 unique BG505 peptides was
achieved by MS (coverage maps are shown in Figures S2
and S3 available online). Expression of both trimers in N-acetyl-
glucosaminyl transferase I deficient (GnTI/) 293S cells aided
the detection of glycosylated peptides during MS analysis, as
the presence of only high-mannose type glycoforms reduced
glycan heterogeneity (Table 1). Peptic fragments from V4 or
the N-terminal half of V1 could not be monitored by HDX-MS.
Their absence was presumably due to dense glycosylation, as
V1 and V4 fragments were observable after the peptic fragments
were deglycosylated with endoglycosidase H (EndoH) or pep-
tide-N-glycosidase F (PNGaseF).
The exchangeprofiles for theKNH1144 andBG505SOSIP.664
trimers are shown in Figure 1; the exchange data for each peptide
are plotted along the primary protein sequence (all individual
exchange plots are shown in Figures S2 and S3). The patterns
of protection were very similar for both trimers. Regions of
high protection were seen throughout the gp120 subunits, as inStructure 22previous studies of gp120 monomers (Davenport et al., 2013;
Guttman et al., 2012) and gp140 monomers (Guttman and Lee,
2013). However, we now also observed extensive protection
within the variable loops of the gp120 subunits in the trimers.
For example, a highly protected region spanned the N-terminal
half of V2 (residues 165–181). Although the region was not
covered in the BG505 data set, there was strong protection
between V1 and V2 up to residue 159 in the KNH1144 data set.
Hence, the region around N160, a central feature of the broadly
neutralizing antibody (bNAb) PG9/16 epitope (McLellan et al.,
2011; Walker et al., 2009), has a stable secondary structure in
the unliganded trimer. In contrast, the rest of V2 (residues 184–
190) undergoes rapid exchange, implying that this relatively short
segment may be the only true flexible ‘‘loop’’ portion of the V2
region. The peptides spanning V3 were also significantly pro-
tected, indicating that in the unliganded trimer, the V3 loop either
has a constrained secondary structure or is solvent inaccessible.
A complex profile of protection throughout the gp41 subunit
provides detailed information about its organization (Figure 1;
Figures S2 and S3). The second half of HR1 (residues 569–592)
is substantially protected, particularly so for residues 579 to
592. In contrast, the N-terminal half of HR1 (residues 546–568),
which contains the I559P substitution integral to SOSIP.664
trimers, was not protected, indicating that this region is not
involved in a stable secondary structure. A moderate level of
exchange protection was seen within the fusion peptide prox-
imal region (FPPR; residues 520–537), whereas the fusion
peptide (FP) itself (as probed via residues 512–519) was fully
exchanged within seconds. The sequence following HR1 (resi-
dues 593–604), including the disulfide loop and the immunodo-
minant epitope cluster I, was also substantially protected. Imme-
diately C-terminal to the disulfide loop, there was only moderate
protection for residues 603 to 622 spanning the N611 and N616/
618 (KNH1144/BG505) glycosylation sites. The rapid exchange
observed in a smaller, overlapping BG505 peptide indicates
that residues 615 to 622 do not have a stable secondary struc-
ture. In HR2, segments 623 to 634 and 641 to 646 are very
strongly protected in the prefusion form of the trimer, while the
intervening segments 635 to 640 (including glycosylation site
N637) are much less well protected. The second half of HR2, 974–984, July 8, 2014 ª2014 Elsevier Ltd All rights reserved 975
Figure 2. HDX-MS Comparisons of 293F versus 293S GnTI–/–
Expression System
(A) The butterfly plot shows the exchange profiles of BG505 SOSIP.664 trimers
from 293S GnTI/ cells (all high-mannose glycoforms, top) versus 293F cells
(contains complex glycosylation, bottom).
(B) The differences at each time point are plotted in the difference plot
underneath, revealing no major changes attributed to differences in glyco-
sylation types.
Table 1. Glycoforms Observed in SOSIP.664 Trimers
Glycosylation Sitesa KNH1144 BG505 (293S) BG505 (293F)
N88 Man5 Man5 Man5 and complex
N156 Man8,9 – –
N188/190 and N190c Man5
b Man5
b,c complex
N197 Man5–9 Man5–9 Man5–9
N234 Man6–9
b Man8,9 Man8,9
N241 Man6–9
b – –
N262 Man8,9 Man8,9 Man8,9
N276 Man7,8 Man5–8 Man5-8
N295 – Man8
c Man8
b
N301 Man7,8 Man8
c Man8
b
N332 and N339 Man8,9
b – –
N356 and N363 Man7
b – –
N448 Man8,9 Man8,9 Man8,9
N463/462 Man5 Man5 complex
N611 and N616/618 Man5
b,c Man5
c complex
N625 Man5
c Man5
c Man5
c
N637 Man5,6 Man5–8 Man5–8
aN-linked glycosylation site(s) where some peptides containedmore than
one glycan; KNH1144/BG505 position.
bData were obtained from peptides bearing two glycans, so only the
average for the total combined glycosylation is reported.
cGlycan occupancy was observed at less than 90%, as assessed by the
relative abundance of nonglycosylated and deglycosylated signal after
PNGaseF digestion (see Tables S1 and S2).
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be highly dynamic in solution. Almost all of the SOSIP.664 pep-
tides exhibited unimodal exchange profiles signifying conforma-
tional homogeneity within the samples, without any evidence of
slow, large-scale, correlated protein motions (EX1 exchange
kinetics). The only exception was fragment 538 to 547, which
exhibited bimodal behavior at early time points in both the
KNH1144 and BG505 data sets (see Figure S4).
Effect of Glycosylation on Underlying Protein Structural
Dynamics
We addressed whether differences in trimer glycosylation affect
the behavior of the underlying protein structure. To do so, we
compared HDX profiles for BG505 SOSIP.664 trimers expressed
in 293F cells (capable of making complex glycans) and 293S
GnTI/ cells (only high-mannose glycans present). The differ-
ences in glycosylation between expression systems were
apparent by SDS-PAGE and blue-native PAGE (BN-PAGE) (Fig-
ure S1). The peptic digest showed that themajority of observable
glycopeptides from 293F-trimers were still in the high-mannose
form, and only glycans at sites N88 and N462 had been pro-
cessed to complex type (Table 1). Because complex glycoforms
are generally harder to detect because of their lower ionization
efficiency and microheterogeneity (Stavenhagen et al., 2013),
we also examined the relative intensities of matched glycopep-
tides derived under identical conditions from BG505 SOSIP.664
trimers that hadbeenproduced in the twodifferent cell types for a
more direct assessment of glycosylation differences (Figure S5).
The signals for the high-mannose glycopeptides at N276, N197,976 Structure 22, 974–984, July 8, 2014 ª2014 Elsevier Ltd All rightsN262, N234, N448, N625, and N637 were relatively consistent
between293Fand293Sdata sets, suggesting that highmannose
glycans are indeed present at all these sites, irrespective of the
cell type used to make the trimers. In contrast, the signal loss
for the high-mannose glycoforms at N88, N190, N462, and
N611/N618 in the 293F data set indicates that the glycans at
these sites had probably been processed to complex types.
Despite the glycosylation differences, the HDX profiles for the
293F and 293S material were very similar (Figure 2), suggesting
that the conformational dynamics of the underlying protein struc-
ture is largely insensitive to any differences in glycan processing.
CD4-Induced Changes within the Trimer
The binding of soluble, two-domain CD4 leads to dramatic
conformational changes that are virtually identical for BG505
and KNH1144 SOSIP.664 trimers, as monitored by HDX-MS
(Figure 3). The most striking changes occurred within V1/V2
and V3, which lost all protection upon CD4 binding. As expected,
the CD4 binding region itself was more protected in the bound
state. Major changes also occurred within regions that comprise
the bridging sheet; strand b21 becamemore protected, whereas
the other three strands (b2, b3, and b20) and the segment directly
C-terminal to b21 were less protected. There was also an
increase in protection within all three layers of the gp120 inner
domain. Within gp41, the FPPR became less protected, whereas
the converse was seen for the C-terminal half of HR1. The slight
protection of the second half of HR2 in the unliganded BG505
trimer was lost upon CD4 binding. A minor fraction the trimer-
CD4 complex showed dimerization when analyzed on BN-
PAGE gels for the BG505, but not the KNH1144 construct
(Figure S1). However, the HDX data yielded no indications of
the presence of multiple Env species, as assessed by the lack
of bimodal distributions in the mass envelopes (Guttman et al.,reserved
Figure 3. Changes upon CD4 Binding by HDX
(A and B) Butterfly plots comparing the exchange profiles for SOSIP.664
trimers unliganded (top) and in complex with sCD4 (bottom) for BG505 (A) and
KNH1144 (B). The corresponding difference plots below highlight the regions
that gain and lose protection upon sCD4 binding, plotted above and below the
axis, respectively.
(C) Regions that are more protected (blue) or less protected (red) upon CD4
binding are mapped on the BG505 SOSIP.664 trimer crystal structure (PDB
Structure
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Structure 222013; Weis et al., 2006). Thus, if some degree of oligomerization
did occur in solution, it did not affect the HDX profile of the
BG505 trimer-CD4 complex.
Oxidative labeling with MS was used as a complementary
approach to track changes in the side-chain solvent accessibility
of BG505 SOSIP.664 trimers upon CD4 binding. Although oxida-
tive labeling was highly reproducible (Figure 4A), the sample-to-
sample variability in digestion efficiency significantly affected the
signal intensities of individual peptides, such that only residues
highly susceptible to oxidation could be monitored reliably (see
Experimental Procedures). We specifically examined residues
M95, M104, M150, M161, F316, M475, and M626, as well as
leucine residues L660, L661, and L663 near the C terminus of
gp41 in this construct (Figure 3C). Whereas M104, M95, and
the triad of gp41 leucines exhibited little response to CD4 bind-
ing, significant changes were observed for M150 and M161 in
V1/V2 and F316 in V3. These residues were all oxidized much
more rapidly after CD4 bound, indicative of a marked increase
in their solvent accessibility (Figure 4B). There was also a slight
increase in the oxidation rate for M626 in gp41 HR2. In contrast,
the oxidation rate at M475 in layer 3 of the gp120 inner domain
was decreased, suggesting that this residue becomes more
buried following CD4 binding.
Effects of Env Inhibitors BMS-806 and NBD-556
To further investigate ligand-induced allosteric changes in the
structure of SOSIP.664 trimers, we used HDX to examine the
effects of two small-molecule compounds that target the CD4
binding site and inhibit a subset of HIV-1 isolates (Zhao et al.,
2005). NBD-556 binds to the Phe43 cavity in gp120 (Kwon
et al., 2012) and induces conformational changes similar to
CD4, at least in the context of monomeric gp120 (Scho¨n et al.,
2006). BMS-806 is also thought to bind at the CD4 binding site
but has been shown to block these same conformational
changes (Guo et al., 2003; Madani et al., 2004). Reported half
maximal inhibitory concentration values for NBD-556 are gener-
ally in the micromolar range (Scho¨n et al., 2006; Zhao et al.,
2005), whereas for BMS-806 they are in the nanomolar range
(Madani et al., 2004; Si et al., 2004). Thus, HDX experiments
with the KNH1144 SOSIP.664 trimers were performed in the
presence of 100 mM of each compound to ensure saturating oc-
cupancy, and all buffers contained 2% DMSO to maintain the
compounds in solution. Under these conditions, the binding of
antibody 17b, which recognizes a CD4-induced epitope overlap-
ping the coreceptor binding site (Thali et al., 1993), to the trimers
was enhanced by NBD-556 but hindered by BMS-806 (Fig-
ure S7A). An additional unliganded HDX data set derived using
the same buffer showed that the inclusion of 2%DMSO hadmin-
imal effects (Figure S7B).
The conformational changes induced in the KNH1144
SOSIP.664 trimer by NBD-556 binding were in part similar to
those seen upon CD4 binding (Figure 5A; cf. Figure 3A). For
example, destabilization occurred within V1/V2 and V3,accession number 4NCO) (Julien et al., 2013a). KNH1144 sequence data were
used for these heatmaps because of the greater coverage, although BG505
shows nearly identical trends for the regions covered. Individual exchange
plots with errors are shown in Figures S2 and S3. Labeled spheres highlight the
specific residues monitored by oxidative labeling.
, 974–984, July 8, 2014 ª2014 Elsevier Ltd All rights reserved 977
Figure 4. Solvent Accessibility Changes upon CD4 Binding Moni-
tored by Oxidative Labeling
(A) Modification rates of peptides used as internal ‘‘dosimeters’’ for ensuring
that both the unliganded and CD4-bound data sets were exposed to similar
amounts of oxidative labeling. The signal for the unmodified form (normalized
to a nonirradiated sample) of leucine enkephalin (left) and Substance P (right)
are shown as a function of exposure to synchrotron radiation.
(B) The degree of oxidation is shown as a function of radiation exposure for
various regions of SOSIP.664 (BG505) in the unliganded (gray circles) or CD4-
bound (squares) state. ‘‘Percentage modified’’ refers to the signal intensity of
Structure
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978 Structure 22, 974–984, July 8, 2014 ª2014 Elsevier Ltd All rightsthroughout the bridging sheet, and even at the FPPR within
gp41. However, in contrast to CD4, NBD-556 binding did not
lead to observable changes in the gp120 inner domain or in
HR1 of gp41 (Figure 5B). In contrast, the binding of BMS-806
altered the trimer in a way that is substantially different to the
effect of CD4, or of NBD-556 (Figures 5C and 5D). When BMS-
806 bound, layers 2 and 3 of the gp120 inner domain became
more protected, with only modest effects on gp41 FPPR and
HR1 and, notably, no major changes in V1/V2 or V3.
DISCUSSION
Structural Organization of Env Trimers in Solution
Cleaved, stabilized SOSIP gp140s are presently the only form of
recombinant soluble trimers with a native-like structure, as
exemplified by the KNH1144 (Bartesaghi et al., 2013; Harris
et al., 2011) and BG505 SOSIP trimers (Julien et al., 2013a,
2013b; Khayat et al., 2013; Lyumkis et al., 2013; Sanders et al.,
2013). The data presented here provide additional evidence
that these SOSIP trimers have conformations consistent with
the functional, prefusion Env structure. In contrast, the alterna-
tive way to make soluble gp140s, by knocking out the intersubu-
nit cleavage site, yields nonnative proteins with heterogeneous,
splayed-out configurations of the gp120 heads held together by
the gp41 stem, which has probably adopted a postfusion (i.e.,
six-helix bundle) state (Guttman and Lee, 2013; Ringe et al.,
2013).
The present analysis gives insight into the underlying structural
dynamics in the unliganded trimer while providing sequence-
specific information about elements that could not be resolved
in the recent 5 A˚ structures. Both the cryo-EM trimer structure
in complex with antibody PGV04 and the crystal structure in
complex with antibody PGT122 were obtained using the same
BG505 SOSIP.664 construct studied here (Julien et al., 2013a;
Lyumkis et al., 2013). These structures revealed how the V1/V2
and V3 variable regions form intimate interactions at the trimer
crown. We find that several regions of V1/V2 do indeed have a
high degree of HDX protection, which is consistent with the
extensive b sheet secondary structure present in the Greek key
motif seen in the PG9-bound scaffolded V1/V2 structure (McLel-
lan et al., 2011) and in the SOSIP.664 trimer structures (Julien
et al., 2013a; Lyumkis et al., 2013). Similarly, the V3 region of
the trimer is extensively protected before, but not after, CD4
binding (Figures 3A and 3B). No such protection of the V1/V2
or V3 regions was seen in our previous studies of monomeric
gp120 (Davenport et al., 2013; Guttman et al., 2012) or mono-
meric, uncleaved gp140 (Guttman and Lee, 2013) implying that
these regions of Env are well ordered only in prefusion trimers.
The slow oxidative labeling kinetics seen for residues M161
and F316 reinforce the assessment that V1/V2 and V3 segments
are largely inaccessible to the solvent in the prefusion form of thethe oxidized from (+16 Da) relative to the sum of signals for the modified and
unmodified peptide, with the sites of oxidation shown in boldface type. Error
bars represent the SD between duplicate measurements. Examples of mass
spectra revealing changes in oxidation rates are shown in Figure S6. The
oxidation sites are illustrated on the trimer in Figure 3C.
*Data for peptide 656 to 664 encompass oxidation at residues L660, L661, and
L663.
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Figure 5. Changes upon NBD-556 and BMS-806 Binding by HDX
(A and B) Butterfly and difference plots showing the effects of NBD-556 (A) and BMS-806 (B) on KNH1144 SOSIP.664 trimers.
(C and D) Differences upon binding NBD-556 (C) and BMS-806 (D) are plotted on the trimer crystal structure (PDB accession number 4NCO), revealing regions
that are more protected (blue) or less protected (red) upon CD4 binding. All of the major changes in the highlighted regions are significant as assessed by the
experimental error (individual plots shown in Figure 6).
Structure
CD4-Induced Changes in Trimeric HIV EnvBG505 SOSIP.664 trimer (Figure 4B). Thus, although V3 is well
exposed on gp120 monomers, our results reinforce its seques-
tration within the trimer structure (Julien et al., 2013a; Lyumkis
et al., 2013).
Although the available structures reveal the overall organiza-
tion of the prefusion form of gp41, for example highlighting a
central helical bundle, much of this subunit has not yet been
interpreted in atomic detail (Julien et al., 2013a; Lyumkis et al.,
2013). The HDX-MS data provide additional sequence-specific
information for gp41 structural order. The N-terminal half of
HR1 (residues 550–568), which contains the I559P gp41-stabiliz-
ing modification, is in rapid exchange and, hence, is not involved
in any stable secondary structure. In contrast, the rest of HR1
(TVWGIKQLQARVLAVERYLRDQQL; residues 569–592) is
extensively protected (Figures 1B and 1C). We infer that the
long central helices observed in the trimer structures (Bartesaghi
et al., 2013; Julien et al., 2013a; Lyumkis et al., 2013) correspond
to residues 569 to 592, rather than the entirety of HR1 (residues
546–586) that is observed as a helix in the postfusion gp41 struc-
ture (Chan et al., 1997).
In both the crystal and EM structures of the BG505 SOSIP.664
trimer, HR2 is proposed to form a long helix. We now find, via
HDX, that the C-terminal helical portion of HR2 (residues 649–
664) is only modestly protected. This region thus appears to beStructure 22more dynamic in solution than is implied by the static structures
in the crystal and in vitreous ice. In contrast, significant segments
in the N-terminal portion of HR2 and the preceding gp41 loop
region are highly protected and, hence, likely to be engaged in
a stable secondary structure. These elements of the trimer are
situated close to the gp120/gp41 interface as they are linked,
via the engineered SOS disulfide bond (C501–C605), to the
C-terminal region of gp120 (Binley et al., 2000). Of note is that
the N- and C-terminal extensions of gp120 are also highly pro-
tected in the trimer but not in gp120 (Davenport et al., 2013; Gutt-
man et al., 2012), again consistent with their involvement in gp41
association (Helseth et al., 1991).
The N-terminal portion of the FP was protected negligibly,
which is surprising because this hydrophobic region might be
anticipated to be solvent occluded in the prefusion state. In a
similar study with influenza hemagglutinin, also a type I fusion
protein, the FP was indeed moderately protected in a way attrib-
utable to either solvent occlusion or hydrogen bonding with res-
idues lining the FP pocket (N.K.G., M.G., J.L. Ebner, and K.K.L.,
unpublished data; Wilson et al., 1981). In Env trimers, the FPmay
be only loosely buried, without any participation of its backbone
in hydrogen bonds. It is also possible that the SOSIP modifica-
tions partially disrupt the packing of the FP. Alternatively, the
membrane-proximal external region, which is absent from the, 974–984, July 8, 2014 ª2014 Elsevier Ltd All rights reserved 979
Figure 6. Key CD4-Induced Changes in Trimeric SOSIP.664 Monitored by HDX-MS
(A) The SOSIP.664 trimer crystal structure (PDB accession number 4NCO) (Julien et al., 2013a) was modeled into the electron microscopic density of unliganded
Env on virions (ElectronMicroscopy Database [EMD] 5019) (Liu et al., 2008): V1/V2 (yellow) and V3 (green), the bridging sheet (red), HR1 (purple), and gp120 inner
domain (black).
(B) The sCD4-bound gp120 core structure (PDB accession number 3JWD) (Pancera et al., 2010) was modeled into the sCD4-bound electron density map (EMD
5455) (Tran et al., 2012) with CD4 shown in blue. In the CD4-bound state, the bridging sheet is reorganized, positioning V1/V2 away from the trimeric interface and
exposing the V3 loop. Individual exchange profiles of the key regions of interest are shown for unliganded trimer (blue), sCD4 bound (red), NBD-556 bound
(orange) and BMS-806 bound (cyan). Error bars represent SDs from duplicate measurements. Electron microscopic renderings were made with Chimera
(Pettersen et al., 2004).
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CD4-Induced Changes in Trimeric HIV EnvSOSIP.664 construct, may play a role in occluding the FP in full-
length, functional trimers.
SOSIP.664 trimers have a much higher content of high
mannose glycans than was found in a previous study of mono-
meric gp120 (Leonard et al., 1990). This finding is consistent
with previous reports that quaternary interactions within Env
trimers occlude several glycan chains from glycosidases and
therefore maintain their high-mannose form (Doores et al.,
2010). Positions N276, N197, and N301, which bear complex
glycans in the context of gp120 monomers and uncleaved
gp140 constructs (Go et al., 2008), show little mannose trimming
and are present as predominantly Man9 and Man8 glycoforms in
SOSIP.664 trimers, even from 293F cells. Because none of these
glycans are part of the 2G12 epitope, the use of a 2G12 affinity
column to purify the trimers is unlikely to skew the observed
glycosylation profiles (Sanders et al., 2002a). Collectively, these
observations may be relevant to immunogen design, because
several of these glycans are involved in bNAb epitopes (Jardine980 Structure 22, 974–984, July 8, 2014 ª2014 Elsevier Ltd All rightset al., 2013; Pancera et al., 2013; Pejchal et al., 2011; Walker
et al., 2011).
CD4-Induced Transitions in Env Trimers
These data provide a detailed glimpse into the CD4-induced
reorganization of the trimer from the closed to the open form, a
process that has been imaged at low-resolution by cryo-EM
(Harris et al., 2011; Liu et al., 2008; Tran et al., 2012). In the
closed, prefusion form, the V1/V2 region is involved in inter-
and intraprotomer interactions that form a cap at the trimer
apex (Figure 6A). Likewise, the V3 and the bridging sheet seg-
ments, which form the coreceptor binding site, are also con-
strained by their involvement in the quaternary structure within
the prefusion trimer. Upon CD4 binding, the structure at the
crown is disrupted, and the V1/V2 and V3 regions become disor-
dered (Figure 3C). The oxidation rates for V2 residues M150 and
M161 and V3 residue F316 are also drastically increased when
CD4 binds (Figure 4B). This increase in the local solventreserved
Figure 7. Allosteric Networks in Env Trimers
CD4 binding leads to two allosteric effects within Env trimers (red to yellow
pathways). Pathways are highlighted on a single protomer of the trimer with
neighboring protomers rendered transparent.
(A) Repositioning of the elements of the bridging sheet leads to the disruption
of the trimeric interactions within V1/V2 and V3, while somehow affecting the
FPPR, whose location and relation to the crown region have yet to be
interpreted in high-resolution structures.
(B) The conformational changes induced within three layers of the inner
domain also influence HR1 within gp41.
Structure
CD4-Induced Changes in Trimeric HIV Envaccessibility is again consistent with an unraveling of the V1/V2
and V3 interactions at the trimer apex as the entire subdomain
structure opens up. Overall, our data illustrate how CD4 binding
acts to disrupt key quaternary interactions and thereby expose
the elements necessary for coreceptor binding and the subse-
quent conformational changes that drive fusion. Moreover, these
same conformational changes uncover various NAb epitopes
that are efficiently shielded on the prefusion form of the trimer,
such as those associated with the coreceptor binding site,
including V3 elements.
The effects of CD4 binding extend beyond the immediate con-
tact zone to the gp120 inner domain as well as to previously unre-
solved elements in gp41. The increased protection of the inner
domain, along with a decrease in solvent accessibility (as probed
by the oxidation rate ofM475), is not surprising given that these re-
gions reside at the interface with CD4. More unexpected was the
large allosteric effect observed in gp41FPPRandHR1.UponCD4
binding, the FPPRbecomes lessprotected, alleviating constraints
around the FP, whereas the center of HR1 becomes more pro-Structure 22tected, possibly a reflection of enhanced packing of the central
helical core. For theBG505 trimers, a slight decrease in protection
at the C-terminal half of HR2 was also evident (Figure 3B). These
alterations to gp41 might serve as an initial priming event prior to
the full activation of Env by coreceptor binding.
CD4 Binding Site-Targeted Ligands Reveal Distinct
Allosteric Networks in Env
A comparison of the effects imparted on Env trimers by the
ligands examined here suggests that two allosteric networks
are engaged when CD4 activates the trimer: one involves ‘‘open-
ing’’ of the Env crown, and the other leads to ‘‘priming’’ of gp41.
The network attributable to ‘‘opening’’ involves rearrangements
of the bridging sheet elements and the disruption of interproto-
mer interactions mediated by V1/V2 and V3 and culminates in
the formation and exposure of the coreceptor binding site (Fig-
ure 7A). The ‘‘priming’’ network links the CD4 binding site to
HR1 through layers 1 to 3 of the gp120 inner domain (Figure 7B).
Whereas CD4 binding triggers both networks, NBD-556 leads
only to the opening of Env and does not appear to prime gp41
(Figures 5 and 6). This mode of action was not evident from
earlier structural studies that used a truncated gp120 core, which
adopts a receptor-bound conformation with an ordered inner
domain that is nearly identical in structure to the CD4-bound
core (Kwon et al., 2012). Conversely, BMS-806 appears to
influence the priming network, without affecting the opening
network. On the basis of our interpretation that residues 569 to
592 correspond to the central gp41 helix, the BMS-806-induced
changes in HR1 appear to be driven through the a1 helix in gp120
layer 2, which like layer 3 also becomes substantially more
ordered (Figures 5D and 7B).
The gp120 inner domain changes that we implicate as part of
the priming pathway are consistent with mutagenesis studies
that probe the transduction of CD4-induced conformational
changes through the inner domain to gp41 (De´sormeaux et al.,
2013; Finzi et al., 2010). It is surprising perhaps that the FPPR
in gp41 responds to both CD4 and NBD-556, whereas the rest
of gp41 appears unchanged by NBD-556 binding. The position
of the FPPR was not interpreted in the existing SOSIP.664 trimer
structures, so its linkage to the opening network is not yet clear.
Overall, our present HDX-MS analysis reveals how CD4 and
CD4 mimetics induce profound conformational changes in the
trimer by activating distinct networks that open the trimer crown,
unmask key elements of the coreceptor binding site, and prime
the fusogenic properties of the gp41 subunit. Further studies
will be required to address how the remaining unmapped
elements of the trimer, and the coreceptor binding event, are
orchestrated to drive the membrane fusion stages of virus entry.
EXPERIMENTAL PROCEDURES
Sample Preparation
KNH1144 and BG505 SOSIP.664 were expressed and purified by 2G12 affinity
chromatography, as described previously (Iyer et al., 2007). A final round of
size exclusion chromatography over a Superdex 200 column (GE Healthcare)
in PBS (20mM sodium phosphate [pH 7.4], 150mMNaCl, 1 mM EDTA, 0.02%
sodium azide) was performed prior to HDX to remove Env aggregates, dimers,
and monomers. Proteins were concentrated with VivaSpin spin filters (GE
Healthcare). Sample purity was assessed with reducing and nonreducing
SDS-PAGE and BN-PAGE (Figure S1). The complex with soluble CD4, 974–984, July 8, 2014 ª2014 Elsevier Ltd All rights reserved 981
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CD4-Induced Changes in Trimeric HIV Env(sCD4) was formed by overnight incubation with a 3-fold molar excess of two-
domain human sCD4 at 4C. sCD4 was obtained from the NIH acquired
immune deficiency syndrome (AIDS) reagents program (Garlick et al., 1990).
BMS-806 was purchased from SelleckChem. NBD-556 was synthesized and
purified as described previously (Scho¨n et al., 2006).
HDX-MS
A 10 mg (80 pmol) aliquot of SOSIP.664 (per time point) was incubated in
deuterated buffer (85%D2O) at 22
C for 3 s, 1 min, 30 min, and 20 hr. Samples
were added to an equal volume (100 ml) of ice-cold quench solution (200 mM
tris(2-carboxyethyl)phosphine, 0.02% formic acid) with 10 ml of a 3 mg/ml
pepsin solution in 100 mM Na3PO4 (pH 4.0), to a final pH of 2.5. After 5 min
of pepsin digestion on ice, samples were flash frozen in liquid nitrogen and
stored at 80C until analysis. Deglycosylated peptic digests were prepared
by treatment with either 0.5 mU of N-glycanase (ProZyme) (pH 7.0) or 0.1
mU EndoH (ProZyme) (pH 5.5) for 2 hr at 37C. Compounds NBD-556 and
BMS-806 were resuspended in DMSO (>99.9%; Sigma-Aldrich) and preincu-
bated with SOSIP.664 at a final concentration of 100 mM in a buffer containing
2% DMSO. Identical compound and DMSO concentrations were included in
the deuterium incubations.
Deuterated samples were analyzed by liquid chromatography (LC)-MS as
previously described (Guttman and Lee, 2013). Peptides were identified by
exact mass and MS/MS spectra with the aid of protein prospector (Baker
et al., 2011). Identification of glycopeptides was aided by MS/MS spectra
of the enzymatically deglycosylated pepsin digests. Deuterium shifts were
calculated with using HX-Express version 2 (Guttman et al., 2013; Weis
et al., 2006) to monitor the mass envelope widths for possible bimodal
behavior. The percentage exchange for each fragment was calculated
relative to zero and fully deuterated standards, as described previously (Gutt-
man et al., 2012). Heatmaps were made using PyMOL (DeLano, 2002).
Because additional GlcNAc groups in complex type glycan chains can
contribute to the observed deuterium uptake kinetics, comparisons of the
exchange kinetics of glycopeptides with different glycan compositions may
be misleading (Guttman et al., 2011). For this reason, the HDX comparisons
between 293S GnTI/ and 293F expressed material were made only with
data from the high mannose glycoforms within the 293F data set, which
were a minor species for sites showing complex type glycosylation. Although
this partially limits the scope of the comparison, if altered glycosylation does
have structural or dynamic effects beyond the glycosylation site, it is likely
that differences in the HDX profiles of peripheral regions will be seen.
Oxidative Labeling
X-ray irradiation experiments were performed at Beamline 4-2 of the Stanford
Synchrotron Radiation Lightsource (SSRL). The X-ray beam (11 keV with a ring
current of 495–500 mA) was attenuated to give dose responses in the
appropriate range for oxidative labeling as assessed on site using samples
containing 80 mMAlexafluor-488 dye in an identical phosphate buffer and ribo-
nuclease A at 1 mg/ml, to mimic sample conditions (Xu and Chance, 2007).
Samples of unliganded and CD4-bound trimer (with a 3-fold molar excess of
sCD4 relative to each SOSIP.664 protomer) in PBS were all prepared at a total
protein concentration of 1 mg/ml to avoid differences in scavenging due to
protein concentration effects (Tong et al., 2008). Leucine enkephalin (330 ng)
and Substance P (580 ng; Sigma-Aldrich) were included in all samples as
internal peptide dosimeters to ensure consistency of labeling between sample
sets (Tong et al., 2008). Samples (20 ml) were loaded with an autosampler using
aMicrolab 560 syringe pump (Hamilton) and irradiated as they passed through
a quartz capillary. The flow rates during irradiation were adjusted to achieve
exposure times ranging from 15 to 240 msec. Immediately after exposure,
the samples were dispensed and mixed into a tube containing 2.5 ml of
200mMmethionine to prevent secondary oxidation (Xu et al., 2005) and stored
at 20C. Samples with no irradiation were collected under identical
conditions to serve as the nonirradiated standards. All experiments were
performed in duplicate.
Irradiated samples were mixed 1:1 with a solution of 6 M guanidine HCl,
20 mM dithiothreitol (DTT) and 50 mM Tris (pH 8.0) and denatured at 85C
for 30 min. Cysteines were then alkylated by incubation in the dark for 1 hr
with 20 mM iodoacetamide, followed by an addition of 10 mM DTT to quench
the reaction. After dilution with 20 mM Tris (pH 8.0) to achieve a final Gnd-HCl982 Structure 22, 974–984, July 8, 2014 ª2014 Elsevier Ltd All rightsconcentration of 0.5 M, samples were treated with 0.5 mU of N-glycanase
(ProZyme) at 37C for 90 min to achieve full enzymatic deglycosylation.
LysC and GluC (Promega) were then added at ratios of 6:1 and 3:1 (substrate
to enzyme) and left at 37C for 18 hr. Samples were analyzed by LC-MS on a
Synapt Q-TOFmass spectrometer coupled to a Aquity UPLC system (Waters).
Peptides were loaded onto a Hypersil 13 50 mm 2.1 mmC18 column (Thermo
Scientific) and resolved with a gradient of 0% to 32% B over 15 min (A: 3%
acetonitrile, 0.1% formic acid; B: 100% acetonitrile, 0.1% formic acid). The
GluC and LysC digests were run in alternating order to minimize any effects
of sample carryover. Chromatographic peaks for the most abundant and
nonoverlapped isotopic peaks were integrated with MassLynx (Waters).
Oxidation rates were initially calculated bymonitoring the net signal intensity
of the unmodified peptide as a function of irradiation dose. Although this type of
analysis was useful for monitoring the oxidation rates of the internal dosimeter
peptides, it was not suitable for the analysis of the Env-derived proteolytic frag-
ments. The high variability in digestion efficiency during sample processing led
to significant variability in the resulting peptide signal intensities. Instead, the
intensity of each modified form of a peptide (+16 Da) was measured relative
to the sum of the modified and unmodified signal intensities (Chen et al.,
2012), a metric that should be independent of digestion efficiency. This
approach provided precise, residue-specific information but limited the scope
of the analysis because only peptides with sufficient degrees of modification
could be analyzed. Peptides and oxidation sites were identified by manual
inspection of MS/MS spectra aided by Protein Prospector (Baker et al., 2011).
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